Anne Zeleniuch-Jacquotte

Professor of Population Health and Environmental Medicine

NYU School of Medicine
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (11)

Supplementary Table S5 shows results of univariate analysis for 77 chronically elevated serum alanine aminotransferase (cALT)-defined nonalcoholic fatty liver disease in the Pancreatic Cancer Case-Control Consortium (PanC4) data

Year:

2025

Supplementary Table S1 shows results of univariate analysis for 77 chronically elevated serum alanine aminotransferase (cALT)-defined nonalcoholic fatty liver disease SNPs in the Pancreatic Cancer Cohort Consortium (PanScan) data

Year:

2025

Supplementary Table S5 shows results of univariate analysis for 77 chronically elevated serum alanine aminotransferase (cALT)-defined nonalcoholic fatty liver disease in the Pancreatic Cancer Case-Control Consortium (PanC4) data

Year:

2024

Supplementary Table S5 shows results of univariate analysis for 77 chronically elevated serum alanine aminotransferase (cALT)-defined nonalcoholic fatty liver disease in the Pancreatic Cancer Case-Control Consortium (PanC4) data

Year:

2024

Background: There are conflicting data on whether nonalcoholic fatty liver disease (NAFLD) is associated with susceptibility to pancreatic cancer (PC). Using Mendelian randomization (MR), we investigated the relationship between genetic predisposition to NAFLD and risk for PC. Methods: Data from genome-wide association studies within the Pancreatic Cancer Cohort Consortium (PanScan; cases n=5090, controls n=8733) and the Pancreatic Cancer Case Control Consortium (PanC4; cases n=4,163, controls n=3,792) were analyzed. We used data on 68 genetic variants with four different MR methods (inverse variance weighting [IVW], MR-Egger, simple median, and penalized weighted median) separately to predict genetic heritability of NAFLD. We then assessed the relationship between each of the four MR methods and PC risk, using logistic regression to calculate odds ratios (ORs) and 95% confidence intervals (CIs), adjusting for PC risk factors, including obesity and diabetes. Results: No association was found between genetically predicted NAFLD and PC risk in the PanScan or PanC4 samples (e.g., PanScan, IVW OR=1.04, 95% CI: 0.88-1.22, MR-Egger OR=0.89, 95% CI: 0.65-1.21; PanC4, IVW OR=1.07, 95% CI: 0.90-1.27, MR-Egger OR=0.93, 95% CI: 0.67-1.28). None of the four MR methods indicated an association between genetically predicted NAFLD and PC risk in either sample. Conclusions: Genetic predisposition to NAFLD is not associated with PC risk. Impact: Given the close relationship between NAFLD and metabolic conditions, it is plausible that any association between NAFLD and PC might reflect host metabolic perturbations (e.g., obesity, diabetes, or metabolic syndrome) and does not necessarily reflect a causal relationship between NAFLD and PC.

Year:

2024

Supplementary Table S1 shows results of univariate analysis for 77 chronically elevated serum alanine aminotransferase (cALT)-defined nonalcoholic fatty liver disease SNPs in the Pancreatic Cancer Cohort Consortium (PanScan) data

Year:

2024

Supplementary Table S1 shows results of univariate analysis for 77 chronically elevated serum alanine aminotransferase (cALT)-defined nonalcoholic fatty liver disease SNPs in the Pancreatic Cancer Cohort Consortium (PanScan) data

Year:

2024

Figure S2 is a forest plot of the association between hypertension and endometrial cancer by study site. It displays the associations between hypertension and endometrial cancer for each study site included grouped by study type (case-control, cohort)

Year:

2024

Figure S2 is a forest plot of the association between hypertension and endometrial cancer by study site. It displays the associations between hypertension and endometrial cancer for each study site included grouped by study type (case-control, cohort)

Year:

2024

Background: The incidence rates of endometrial cancer are increasing, which may partly be explained by the rising prevalence of obesity, an established risk factor for endometrial cancer. Hypertension, another component of metabolic syndrome, is also increasing in prevalence, and emerging evidence suggests that it may be associated with the development of certain cancers. The role of hypertension independent of other components of metabolic syndrome in the etiology of endometrial cancer remains unclear. In this study, we evaluated hypertension as an independent risk factor for endometrial cancer and whether this association is modified by other established risk factors. Methods: We included 15,631 endometrial cancer cases and 42,239 controls matched on age, race, and study-specific factors from 29 studies in the Epidemiology of Endometrial Cancer Consortium. We used multivariable unconditional logistic regression models to estimate ORs and 95% confidence intervals (CI) to evaluate the association between hypertension and endometrial cancer and whether this association differed by study design, race/ethnicity, body mass index, diabetes status, smoking status, or reproductive factors. Results: Hypertension was associated with an increased risk of endometrial cancer (OR, 1.14; 95% CI, 1.09–1.19). There was significant heterogeneity by study design ( P het Conclusions: Hypertension is associated with endometrial cancer risk independently from known risk factors. Future research should focus on biologic mechanisms underlying this association. Impact: This study provides evidence that hypertension may be an independent risk factor for endometrial cancer.

Year:

2024

Year:

2024

Collaborators (51)

Rayjean Hung

University of Toronto

CANADA
View details

Neal Freedman

Branch Chief

National Cancer Institute

UNITED STATES
View details

Christopher A. Haiman

University of Southern California

UNITED STATES
View details

Carlo La Vecchia

Professor of Epidemiology

Università degli Studi di Torino

ITALY
View details

Ian M. Thompson

University of Texas Health Science Center at San Antonio

UNITED STATES
View details

Anna E. Prizment

Faculty, Associate Professor

University of Minnesota

UNITED STATES
View details

Xiao‐Ou Shu

Vanderbilt University Medical Center

UNITED STATES
View details

Lynne Wilkens

Professor

University of Hawaii at Manoa

UNITED STATES
View details

Sven Sandin

Associate Professor

Karolinska Institutet

SWEDEN
View details

Carlotta Sacerdote

Docenti di ruolo di Ia fascia

Università degli Studi del Piemonte Orientale Amedeo Avogadro

ITALY
View details

Anne Tjonneland

Professor

Københavns Universitet

DENMARK
View details

Fulvio Ricceri

University of Turin

ITALY
View details

Piet van den Brandt

Professor of Epidemiology

University of Maastricht

NETHERLANDS
View details

P. M. Webb

Group Leader

QIMR Berghofer Medical Research Institute

AUSTRALIA
View details

Noah Peeri

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Tracy O'Mara

Team Head

QIMR Berghofer Medical Research Institute

AUSTRALIA
View details

Ulrike Peters

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Julie R Palmer

Boston University School of Medicine

UNITED STATES
View details

Leo Schouten

University of Maastricht

NETHERLANDS
View details

Wei Zheng

-

UNITED STATES
View details

Miquel Porta

-

UNITED STATES
View details

Peter Kraft

Professor

Harvard T.H. Chan School of Public Health

UNITED STATES
View details

Kari Rabe

Assistant Professor of Biostatistics

Mayo Clinic

UNITED STATES
View details

Stephen Chanock

National Institutes of Health

UNITED STATES
View details

Alison Klein

Professor

-

UNITED STATES
View details

Linda Cook

Professor

University of Colorado Cancer Center

UNITED STATES
View details

Federico Canzian

Group Leader

Deutsches Krebsforschungszentrum

GERMANY
View details

Herbert Yu

Researcher/Professor

University of Hawaii at Manoa

UNITED STATES
View details

Martijn C.G.J. Brouwers

-

NETHERLANDS
View details

Fabio Parazzini

University of Milan

ITALY
View details

Michele L. Cote

Indiana University

UNITED STATES
View details

Thilo Hackert

University Hospital Heidelberg

GERMANY
View details

Elio Riboli

Professor of Cancer Epidemiology

Imperial College London

UNITED KINGDOM
View details

Rachael Solomon

Senior Eoidemiologist

Division of Cancer Epidemiology and Genetics, National Cancer Institute

UNITED STATES
View details

Jean Wactawki-Wende

Dean, Suny Distinguished Professor

University at Buffalo

UNITED STATES
View details

Malin Sund

Professor/Consultant

University of Helsinki

FINLAND
View details

Loic Le Marchand

Professor

University of Hawaii

UNITED STATES
View details

Donghui Li

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jo Freudenheim

SUNY Distinguished Professor and Associate Dean

University at Buffalo

UNITED STATES
View details

Alan Arslan

Associate Professor

NYU Langone Medical Center

UNITED STATES
View details

Eva Negri

Associate professor

University of Bologna

ITALY
View details

Nuria Malats

Group Leader

Centro Nacional de Investigaciones Oncológicas

SPAIN
View details

Kala Visvanathan

Professor

Johns Hopkins University

UNITED STATES
View details

Manal M. Hassan

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Veronica Setiawan

Associate Professor

University of Southern California

UNITED STATES
View details

Susan J. Jordan

Associate Profesor

University of Queensland

AUSTRALIA
View details

Charles Kooperberg

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Lingeng Lu

Yale School of Public Health

UNITED STATES
View details

Kimberly A. Bertrand

Associate Professor of Medicine

Boston University

UNITED STATES
View details

Graham Giles

Head of Research

-

AUSTRALIA
View details

Manolis Kogevinas

Senior Researcher

Barcelona Institute for Global Health

SPAIN
View details